Background and Aims: This review is the first to evaluate the burden of ulcerative colitis [UC] on patients' quality of life by synthesizing data from studies comparing scores from the SF-36® Health Survey, a generic measure assessing eight quality-of-life domains, between UC patients and matched reference samples. Methods: A systematic review of the published literature identified articles reporting SF-36 domains or physical and mental component summary scores [PCS, MCS] from UC and reference samples. Burden of disease for each SF-36 domain was then summarized across studies by comparing weighted mean differences in scores between patient and reference samples with minimally important difference thresholds.
Introduction
Patients with ulcerative colitis [UC] experience recurring and episodic clinical signs and symptoms, including anaemia, rectal bleeding, diarrhoea, abdominal pain, and fecal urgency. 1 However, patients express concerns that go beyond these clinical manifestations. They report anxieties stemming from a lack of control over their bodily functions, fear of disease progression, hospitalization, or surgery, and fear of not having immediate access to a toilet. [2] [3] [4] The issue of toilet access further affects their employment opportunities and work productivity, [4] [5] [6] and limits their ability to engage in social and recreational activities. 2, 4, 6, 7 Impaired ability to develop and maintain strong relationships with others may contribute to problems with anxiety, isolation, and depression that are common in this patient population. [8] [9] [10] [11] Physicians typically underestimate the burden of UC on patients' daily functioning and well-being 12 ; patients are twice as likely as physicians to endorse statements such as 'living with UC is a daily struggle', and 'UC has wrecked important moments in my life'. 13 Thus, fully capturing the burden of UC on the health status of patients with active disease, and accurately evaluating the degree to which treatment alleviates this burden, entails more than merely assessing changes in intestinal symptoms or mucosal inflammation; it also requires measuring changes in patients' functioning and well-being.
The SF-36® Health Survey [SF-36] is a generic patient-reported outcome [PRO] measure that captures multiple aspects of how a respondent feels and functions in their daily life.
14 Because constructs captured by the SF-36 are not specific to a particular health condition or treatment, the interpretation of the burden of a particular condition, such as UC, can be assessed by comparing scores from persons with a condition to scores from a comparable reference, such as a gender-and age-matched control group or the general population. Subsequently, one can understand the impact of treatment or a change in disease status [e.g. achieving disease remission] not merely in a relative sense, such as whether patients' symptoms improve, but also in an absolute sense: whether they become 'well' or normalized.
The objective of the current study was to conduct the first systematic examination of the burden of disease for patients with UC, as measured by SF-36 scores relative to population norms or matched controls. We conducted a review of published studies that reported SF-36 scores from both UC patients and a relevant reference group-a group that is generally healthy and without UC-to assess the magnitude of differences in their SF-36 scores. Burden was examined separately for: samples in which all patients had active disease; samples that included a mix of patients with active and inactive disease; samples of patients in clinical remission; and samples in which patients had undergone surgical treatment [i.e. proctocolectomy with either ileal pouch-anal anastomosis [IPAA] , ileorectal anastomosis [IRA], or ileostomy]. Whereas it is generally known that patients with active disease experience functional impairments, the degree to which these impairments are reduced, or fully eliminated, in patients with medical-or surgically-induced remission is not as apparent.
Methods

SF-36® health survey [SF-36]
The SF-36 is a 36- 19 ,20 have been derived from a representative adult sample from the US general population, who participated in the 1998 National Survey of Functional Health Status. 15 All T-scores for the SF-36v1 and SF-36v2 [heretofore, each referred to as 'SF-36'] reported in this paper were calculated using the algorithms based on the 1998 norms dataset.
Thresholds indicating minimal important differences [MIDs] between samples, which can be interpreted as clinically meaningful group differences, 23 have been estimated for each SF-36 scale and summary score using both distribution-based and anchor-based approaches. 15 The MID thresholds recommended by the instrument's developers for between-group differences in SF-36 , and BIOSIS Previews-as well as Optum's in-house bibliography that tracks publications using its proprietary survey tools, including the SF-36. The search terms and strings used, which are reported in Supplementary Figure 1 [available as Supplementary data at ECCO-JCC online], were designed to capture studies in which the SF-36 was administered to patients with UC or inflammatory bowel disease [IBD] in general.
Article selection
All stages of article selection were conducted by three independent researchers. After each stage, any discrepancies among reviewers regarding the selection decision for each article were discussed until a consensus was obtained.
Initial screening was based on review of record titles, abstracts, and metadata. Records were selected if they met all of the following inclusion criteria: the record pointed to a full article [i.e. not a conference abstract]; the article was published in an English language, peer-reviewed journal; the article described quantitative results from an empirical study; and the article was not clearly irrelevant to the current objectives.
The full text of each article selected during initial screening was reviewed. Articles meeting the following criteria were selected for data extraction: mean or median SF-36 domain scores were reported for a sample or subsample consisting of only UC patients; SF-36 domain scores were also reported from an appropriate reference sample [e.g. matched control sample, general population sample from the same geographical region]; and SF-36 scores were calculated using developer-approved algorithms.
Data extraction
We extracted mean or median SF-36 domain and/or summary scores from each selected article. For studies using longitudinal designs, we extracted scores from baseline visits only. For articles that presented SF-36 scores in figures rather than numerically in tables or text, we estimated numerical values using WebPlotDigitizer desktop software (version 3.9; available at [http://arohatgi.info/WebPlotDigitizer]). 22 Articles reporting raw domain scores [0-100] were transformed to T-scores using Optum's scoring algorithms appropriate to the version used [SF-36v1 or SF-36v2] as derived from the 1998 norm dataset, followed by calculation of PCS and MCS scores using the corresponding weights. 15 
Assessment of disease burden within each study
We calculated disease burden for UC patient samples within each study by subtracting mean or median SF-36 T-scores for the UC patient sample from T-scores reported for the study's reference sample. The presence or absence of disease burden was determined by comparing the magnitude of between-sample differences with MID thresholds [i.e. differences above the MID threshold indicated the presence of disease burden].
Summary of disease burden across studies
Based on reported characteristics of patients at the time that the SF-36 was administered, we classified samples into one of four categories based on pre-specified ad hoc criteria: active disease [≥80% of sample patients had active disease]; mixed disease activity [≥20% and <80% of sample patients had active disease or were in clinical remission]; remission [≥80% of sample patients were in clinical remission]; and post-surgical [sample patients had undergone proctocolectomy with IPAA, IRA, or ileostomy]. For each SF-36 domain and summary measure, we summarized difference scores across studies within each category by calculating unweighted mean values as well as mean values when weighted by the number of patients in the UC sample and when weighted by the combined UC and reference samples. We then compared these summary statistics for each measure with corresponding MID values to assess burden across all samples within the category, and calculated the percentage of samples within each category for which a value exceeding the MID was observed.
Results
Literature search
The number of articles retrieved from each data source, and the number of unique articles excluded from the review during initial screening and full-text review, are presented in Supplementary  Figure 2 , [available as Supplementary data at ECCO-JCC online]. SF-36 scores were extracted from 30 articles that met all selection criteria. 27, 30, [33] [34] [35] 40, 43, [47] [48] [49] 52 proctocolectomy with ileostomy in two samples, 29, 32 and proctocolectomy with IRA in one sample. 35 
Disease burden for samples of patients with active UC
We observed evidence supporting clinically meaningful burden in most SF-36 domains for samples of patients with active disease [ Table 2 ]. Across the five active disease samples, the weighted mean differences in scores exceeded MID thresholds for Role Physical, Bodily Pain, perception of General Health, Vitality, Social Functioning, and Mental Health domains, as well as for PCS and MCS. The mean difference weighted by the combined UC and reference samples, but not by the UC sample alone, exceeded the MID threshold for the Role Emotional domain, whereas neither exceeded the MID threshold for the Physical Functioning domain. Comparisons exceeded MIDs in the majority of samples for both summary scores and for all domains other than Physical Functioning.
Disease burden for samples of patients with mixed active and inactive UC
Findings for disease burden for mixed disease activity samples are presented in Table 3 . Across the eleven samples in this category, both of the weighted mean differences in scores exceeded MID thresholds for Role Physical, Bodily Pain, perception of General Health, Vitality, and Social Functioning domains, as well as for PCS. The mean difference weighted by the combined UC and reference samples, but not by the UC sample alone, exceeded the MID threshold for the remaining domains [Physical Functioning, Role Emotional, and Mental Health] as well as the MCS. Comparisons exceeded MIDs in the majority of samples for both summary scores and for all domains other than Physical Functioning. Table 4 presents assessment of disease burden in samples of patients in clinical remission. Across the four remission samples, both of the weighted mean differences in scores exceeded MID thresholds only for the perception of General Health domain, but neither of these differences exceeded the MID threshold for any of the remaining domains nor for either summary measure. Correspondingly, comparisons exceeded MIDs in the majority of samples for only the perception of General Health domain; comparisons exceeded MIDs in two of the four studies for the Vitality domain, and in one or no studies for both summary measures and the remaining domains. Given the observed similarity in patterns of burden for the active disease samples and the mixed activity disease samples, we compared weighted mean differences between the two sets of samples to determine whether the magnitude of burden between samples exceeded the MID threshold. No differences exceeded MID thresholds for any domain or either summary measure for either of the weighting sets, indicating that the active and mixed activity samples had the same magnitude of burden, and thus could be combined into a single set of samples [active/mixed UC samples set]. The same approach was used to determine that the remission and post-surgical samples had comparable burden, and thus could also be combined into a single set of samples [remission/post-surgical UC samples set].
Disease burden for samples of patients with UC in remission
Disease burden for samples of post-surgical UC patients
We compared the magnitude of burden in SF-36 scores for the active/mixed UC samples set and for the remission/post-surgical UC samples set based on the weighted [by combined samples] ASA, aminosalicylic acid; CAI, Colitis Activity Index; CDAI, Crohn's Disease Activity Index; GI, gastrointestinal; GP, general population; IBD, inflammatory bowel disease; IPAA, ileal pouch-anal anastomosis; IRA, ileorectal anastomosis; NOS, not otherwise specified; SCCAI, simple clinical colitis activity index; TNF, tumour necrosis factor; UC, ulcerative colitis. Figure 1 ]. The results indicate that the magnitude of burden in the active/mixed UC samples set exceeds that for the remission/post-surgery samples set, on all eight domains and both summary scores. Further, for the active/mixed UC samples set, the lower limits of the 95% CIs for weighted mean differences exceed the MID for both summary scores, and for all domains except for Physical Functioning. At the same time, 95% CI limits for the remission/post-surgery UC samples set overlap with or are actually below 0, indicating a complete lack of burden, for both summary scores and for six of the eight domains. For this set of UC samples, clinically meaningful burden of disease is only observed for the perception of General Health domain.
Discussion
Findings from this review of published studies comparing SF-36 scores between UC patients and reference samples indicate very different burden profiles between patients with active and inactive disease. Patients with active disease showed deficits relative to controls that exceeded established MID thresholds in all measured aspects of functioning and well-being, with the exception of Physical Functioning. The largest impact of disease was observed on patients' perception of General Health. The impacts of active UC on Role Physical and Social Functioning domains were also substantial. The sizeable burdens of active UC on these latter two domains of functioning are consistent with concerns that are often mentioned by patients, such as decreased performance at work/school, limitations Mean differences were weighted by the size of the UC sample. c Mean differences were weighted by the combined size of the UC and reference samples. in the ability to engage in social activities due to the need for access to a toilet, and the subsequent difficulties for maintaining relationships with others. [2] [3] [4] [5] [6] [7] In contrast, patients with inactive disease [as indicated by assessed clinical remission, or surgically-induced remission] were comparable to healthy controls or general population samples on all domains of physical and mental functioning with the exception of perception of General Health. In other words, achieving an inactive disease state, via clinical remission or using surgery, does not simply reduce the impact of disease on how patients feel and function, but it eliminates the burden altogether, normalizing both physical and mental health status. However, although these patients reported normal levels of functioning and well-being, they still described residual concerns about their health in general. It may be that a longer follow-up of patients with inactive disease would reveal that their general health perceptions also reached normal levels.
In clinical trials, the perspective of patients with UC is often assessed using disease-specific measures of symptoms and their impact on functioning and well-being, such as the Inflammatory Bowel Disease Questionnaire [IBDQ] . The use of disease-specific PRO measures to evaluate treatment benefit is important, as these instruments capture health concepts directly relevant to disease Mean differences were weighted by the combined size of the UC and reference samples. symptoms, and are typically more responsive to improvements in UC patients' clinical and endoscopic disease activity than are generic measures. 54 At the same time, disease measures are, by definition, narrow in scope with respect to the concepts they capture, and typically only assess aspects of health directly related to the affected organ or its treatment. In contrast, generic measures such as the SF-36 capture a broader array of health concepts. An additional benefit of using a generic, normed instrument is the ability to compare health outcomes with persons outside the patient population, such as understanding the relative burden of disease as described here. Thus, disease-specific and generic PRO measures offer complementary information and interpretability for understanding treatment benefit, and as such the inclusion of both types of measures [specifically, the SF-36 and IBDQ] has been recommended for use in clinical trials with UC patients. 55 There are some limitations to the current study that should be considered when interpreting these findings. For example, we limited our analysis to studies that reported scores from a sample of UC patients as well as from a reference group. Whereas this criterion was helpful in selecting a reasonable number of studies with data relevant to the current objectives, it is possible that patients in studies meeting these criteria are not representative of the UC patient population. For instance, researchers studying patients with active UC who have particularly poor functioning may be more likely to compare patients' outcomes with a reference sample to highlight this burden. On the other hand, researchers studying patients with inactive UC who have particularly good functioning may be motivated to exhibit the benefits of improving health outcomes by comparing patients' outcomes with a reference sample, to demonstrate their similarity.
Additionally, our classification of samples was based on patients' disease status characteristics, but we could not control for any other factors that may have varied between these samples which could account for patterns of disease burden reported here. Thus, we cannot definitively rule out other factors that contribute to the disease burden observed across the sample groups.
Conclusion
In conclusion, our synthesis of data from a systematic review of the published literature provides the first clear evidence that UC patients with active disease experience burdens on physical, emotional, and social functioning and well-being, and that normalization of these outcomes is observed in patients with inactive UC. Our findings suggest that treatments for patients with UC which induce and maintain disease inactivity may not simply make patients better, but rather may normalize physical and mental health status.
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